INTEGRA®

LIMIT UNCERTAINTY

Q3 2023 EARNINGS PRESENTATION

OCTOBER 25, 2023

Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” "forecast," "guidance," “plan,” “anticipate,” “target,” or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this presentation include, but are not limited to, statements concerning future financial performance, including projections for revenues, expected revenue growth (both reported and organic), GAAP and adjusted net income, GAAP and adjusted earnings per diluted share, non-GAAP adjustments such as divestiture, acquisition and integration-related charges, intangible asset amortization, structural optimization charges, EU Medical Device Regulation-related charges, charges related to the voluntary global recall of products manufactured at the Company’s Boston, Massachusetts facility, and income tax expense (benefit) related to non-GAAP adjustments and other items, and expectations and plans with respect to the Company’s ability to resume manufacturing activities at its Boston facility, strategic initiatives product development and regulatory approvals, including the status of the Company’s 510(k) premarket notification for Cerelink. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, inflation, supply chain disruptions, trade regulation and tariffs, other economic disruptions and U.S. and global recession concerns, on the Company’s customers and on the Company’s business, financial condition, results of operations and cash flows; the Company's ability to execute its operating plan effectively; the Company’s ability to successfully integrate acquired businesses; the Company’s ability to achieve sales growth in a timely fashion; the Company's ability to manufacture and ship sufficient quantities of its products to meet its customers' demands; the ability of third-party suppliers to supply us with raw materials and finished products; global macroeconomic and political conditions, including as a result of the Russian Federation-Ukraine conflict and conflict involving Israel and Gaza; the Company's ability to manage its direct sales channels effectively; the sales performance of third-party distributors on whom the Company relies to generate revenue for certain products and geographic regions; the Company's ability to access and maintain relationships with customers of acquired entities and businesses; physicians' willingness to adopt and third-party payors' willingness to provide or maintain reimbursement for the Company's recently launched, planned and existing products; increasing industry competition; the Company's ability to secure regulatory approval for products in development; the Company's ability to remediate quality systems violations; fluctuations in hospitals' spending for capital equipment; downward pricing pressures from customers; the Company's ability to comply with regulations regarding products of human origin and products containing materials derived from animal source; difficulties in controlling expenses, including costs to procure and manufacture our products; the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions; the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company’s ability to achieve anticipated growth rates, margins and scale and execute its strategy generally; the amount and timing of divestiture, acquisition and integration-related costs; the geographic distribution of where the Company generates its taxable income; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the EU Medical Devices Regulation; the scope, duration and effect of additional U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; the Company’s ability to commence any share repurchase activity, including within the anticipated timeframe; potential negative impacts resulting from environmental, social and governance matters; the Company's ability to execute on its and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2022 and information contained in subsequent filings with the Securities and Exchange Commission.

These forward-looking statements are made only as of the date hereof, and, except as otherwise required by applicable law, the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.

Non-GAAP Financial Measures

In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, organic revenues excluding Boston, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, adjusted gross profit, adjusted gross margin, free cash flow and adjusted free cash flow conversion. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures and discontinuances. Organic revenues excluding Boston consist of total revenues excluding (i) the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures and discontinuances and (ii) revenues associated with Boston produced products including sales reported prior to the recall and the impact of sales return provisions recorded. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); and (v) those operating expenses also excluded from adjusted net income. The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) charges related to the voluntary global recall of products manufactured at the Company's Boston, Massachusetts facility; (v) intangible asset amortization expense; and (vi) income tax impact from adjustments. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. Adjusted gross profit consists of GAAP gross profit adjusted for: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) discontinued product lines charges; (iv) EU Medical Device Regulation-related charges; and (v) intangible asset amortization expense. The measure of adjusted gross margin is calculated by dividing adjusted gross profit by total revenues. The measure of free cash flow consists of GAAP net cash provided by operating activities less purchases of property and equipment. The adjusted free cash flow conversion measure is calculated by dividing free cash flow by adjusted net income.

Reconciliations of GAAP revenues to organic revenues, GAAP revenues to organic revenues excluding Boston, GAAP adjusted net income to adjusted EBITDA and adjusted net income, GAAP earnings per diluted share to adjusted earnings per diluted share, GAAP gross profit to adjusted gross profit, GAAP gross margin to adjusted gross margin, and GAAP total debt to net debt all for the quarters ended September 30, 2023 and 2022, and the free cash flow and adjusted free cash flow conversion for the quarters and twelve-months ended September 30, 2023 and 2022, appear in the financial tables in this presentation.

The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this presentation filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.

Boston Update

Status Update

- Defined holistic remediation plan consistent with requirements outlined by the FDA in July ‘23 warning letter
- Reinforced Boston leadership and project team with internal resources and outside experts
- Completed interim external reviews in preparation for factory restart
- Remediation remains on track with timelines previously communicated
- Product substitutions are in-line with expectations of 10-15%
- SurgiMend® PMA approval timing on track for 1H’25

Key Upcoming Milestones

- ✓ Interim external progress reviews confirm adequacy of plan and execution
- ❑ Factory restart by end of Q4’23
- ❑ External review post factory restart to prepare for final external audit
- ❑ Final external audit completed and submitted to the FDA by 3/31/24
- ❑ Building inventory to support distribution
- ❑ Resume distribution mid-to-late Q2 2024

Financial Impact

2023

- Boston returns negatively impacted Q3 revenue and adj. EPS by approximately $7 million and 7 cents, respectively
    - Customer returnable inventory levels substantially assessed and reconciled
- Expect full-year 2023 revenue and adj. EPS impact of approximately -$67 million and -42 cents, driven by lost sales and returns, partially offset by cost savings in 2H’23

2024

- No change to preliminary full-year 2024 Boston impact provided in July[1]
- 2024 guidance will be provided as part of Q4’23 earnings release in February

Factory restart and return to market timelines remain on track; additional returns provision in Q3

[1]Includes: Lost revenue partially offset by revenue substitutions; OPEX savings and impact of share repurchase

Executing On Our Strategy

Business Highlights

Innovating for Outcomes

- Relaunched CereLink® in select international markets and submitted 510(k) for CereLink in the U.S.; expect U.S. launch early Q1'24
- Submitted 510(k) for next generation Aurora® Surgiscope

Grow International

- Continued market expansion of CUSA® platform with Clarity Stage 3, Laparoscopic tip and Single Sided Bone Tip launched in Saudi Arabia
- Broadened International registrations of DuraGen®, DuraSeal®, Mayfield®, Duo LED , Electro Surgery in LATAM and EMEA
- Launched DuraGen Plus in China
- Began buildout of leased In-China-for-China manufacturing facility

Broaden Impact on Care Pathways

- Successful commercial and clinical integration of SIA acquisition
- Expanded A-Cell UBM platform with 510k clearance for MicroMatrix® Flex

Strengthened executive leadership with the appointment of Chantal Veillon as Chief Human Resources Officer

Issued 2022 ESG report

Q3 Financial Performance

Total revenue $382.4 million

-0.4% organic growth (+7.1% excl. Boston)

- CSS +7.4% (US +3.2%; Int'l +14.8%)
- TT -15.1% (+6.7% excl. Boston)
- ~$7M increase to Boston recall returns provision drives guidance miss
- DD growth in Mayfield capital, Certas® Plus, Bactiseal®, DuraGen, DuraSeal, ICP microsensors, cranial access kits, MicroMatrix, Cytal®, Gentrix® and amniotics; MSD growth in Instruments
- Strong International organic growth at +11.8%

Adj. EPS $0.76

- Adj. gross margin of 64.6% down 210bps from prior year, ~180bps from Boston recall including ~$7M increase in the returns provision

FY 2023 Guidance

Revenue	$1.541B-$1.547B
Organic Growth	0.1%-0.5% (~6% excl. Boston)
Adjusted EPS	$3.10-$3.14

Boston returns overshadow strong underlying growth dynamics

Note: Organic growth (including organic growth excluding the impact of the Boston recall), adj. earnings per share, and adj. gross margin are non-GAAP financial measures.

Third Quarter Financial Highlights



Revenue and profitability performance impacted by Boston; Adj. EPS within guidance

[1]Q3 2023 excludes $1.4M related to discontinued and divested products, $2.9M of acquired SIA revenues and $1.0M in foreign exchange; Q3 2022 excludes $6.5M related to discontinued and divested products
Note: Organic growth, adj. earnings per share, adj. EBITDA margin and adj. gross margin are non-GAAP financial measures.

Codman Specialty Surgical Q3 Revenue

Revenues	Q3'23	Q3'22	Growth
Reported	$268.2M	$249.8M	7.4%
Organic[1]	$265.9M	$247.7M	7.4%

Q3 2023 Growth and Performance Drivers[2]		
Neurosurgery	**Instruments**	**International**
8.0%	5.0%	Double-Digit growth

- Neurosurgery – Low double-digit growth in both CSF management, driven by Certas Plus valves, and Neuro Monitoring, driven by ICP microsensors; high-single digit growth in Dural Access and Repair, driven by Mayfield, DuraGen and DuraSeal; mid single-digit decline in Advanced Energy due to CUSA capital order timing
- Instruments – Mid-single growth, driven by strong demand and site of care expansion
- International – Low double-digit growth attributable to double-digit growth in China, indirect markets, ANZ, and Canada

Q3 2023 Revenue Composition



Strong global demand in Neurosurgery and Instruments

[1]Q3 2023 excludes $1.4M related to discontinued and divested products and $0.9M in foreign exchange; Q3 2022 excludes $2.1M related to discontinued and divested products
[2]Percentages based on organic revenue; Commentary represents organic performance; Comparisons are to prior year

Tissue Technologies Q3 Revenue

Revenues	Q3'23	Q3'22	Growth	*Growth excl. Boston*
Reported	$114.2M	$135.4M	-15.6%	*5.4%*
Organic[1]	$111.2M	$131.0M	-15.1%	*6.7%*

Q3 2023 Growth and Performance Drivers[2]		
Wound Reconstruction	**Private Label**	**International**
-15.5%	-13.9%	Down Low-Double-Digits

- Wound Reconstruction – Boston recall impact partially offset by double-digit growth in MicroMatrix, Cytal, Gentrix, and amniotics
  - >100% growth in DuraSorb YTD[1]
- Private Label – Low-double-digit decline driven by Boston recall
- International – Down low-double-digits primarily driven by the Boston recall, partially offset by double-digit growth in Integra Skin, MicroMatrix and Cytal

Q3 2023 Revenue Composition



Strong organic growth in Wound Reconstruction, excluding the impact of Boston

[1]Q3 2023 organic growth excludes $2.9M of acquired SIA (DuraSorb) revenues and $0.1M in foreign exchange; Q3 2022 excludes $4.4M related to divested products
[2]Percentages based on organic revenue; Commentary represents organic performance; Comparisons are to prior year

Q3 2023 Financial Results ($M except per share data)

Total Revenue	Adj. Gross Profit	Adj. EBITDA	Adj. EPS
Reported (0.7%) Organic (0.4%)	(210bps) Margin	(430bps) Margin	(11.6%) EPS



- Revenue: broad demand strength from DuraGen, DuraSeal, Mayfield, Certas Plus programmable valves, Instruments, MicroMatrix, Gentrix , Cytal, and amniotics, offset by Boston recall impact
- Adj. Gross Margin: down 210 bps primarily due to ~180 bps from the Boston recall and yield inefficiencies, partially offset by favorable mix
- Adj. EBITDA Margin and adj. EPS: down 430bps and 11.6%, respectively, driven by Boston recall, planned investments in key strategic priorities, and year-one dilution from the SIA acquisition

Revenue and profitability down vs prior year driven by Boston recall

Note: Organic growth, adj. gross margin, adj. EBITDA margin and adj. EPS are non-GAAP financial measures.

Balance Sheet and Cash Flow Performance

Summary Balance Sheet ($M)	12/31/22	9/30/23
Cash and Cash Equivalents	$457	$274
Total Debt	$1,455	$1,516
Net Debt	$998	$1,242
Available Credit	$1,299	$1,208
Total Available Liquidity	$1,756	$1,482
Consolidated Total Leverage Ratio	2.2x	3.0x

Operating Cash Flow, Free Cash Flow ($M) & Adj. FCF Conversion (%)



Strong balance sheet enables flexible capital allocation; FCF reflects safety stock and EU MDR inventory builds

Note: Adj. FCF conversion is a non-GAAP financial measure; Numbers may not add due to rounding

Q4 and FY 2023 Outlook

Q4 2023 Reported Revenue Guidance Bridge ($M)



FY 2023 Reported Revenue Guidance Bridge ($M)



Q4 2023

- Revenue: $397M-$403M
  - Reported Growth -0.4% to +1.1%
  - Organic Growth -0.8% to +0.7%
- Adj. EPS $0.89 - $0.93

FY 2023

- Revenue: $1.541B-$1.547B
  - Reported Growth -1.1% to -0.7%
  - Organic Growth +0.1% to +0.5%
- Adj. EPS $3.10 - $3.14

Guidance updated to reflect full-year impact of Boston recall and solid underlying business performance

Note: Organic growth and adj. EPS are non-GAAP financial measures.

Note: Q4 assumes EURUSD rate of 1.06, USDJPY 150, USDCNY 7.30, adj. tax rate of 17% and ~79 million weighted avg. common shares outstanding

De-risking our path to LRP growth and consistent delivery of our financial commitments

✓ Solid progress on Boston restart, with timelines on track

- Interim external reviews confirm adequacy of remediation plan and changes made
- Expect to restart manufacturing in Boston by end of Q4’23 and resume commercial distribution in mid- to late Q2’24
- Product substitution rate is in line with expectations of 10-15%
- SurgiMend PMA approval timing on track for 1H’25

✓ Strong underlying Q3 growth performance, offset by Boston recall impact

- 7.1% organic growth in Codman Specialty Surgical and Tissue Technologies (excluding Boston)
- Resilient, diverse portfolio with double-digit growth in several product lines
- 11.8% growth in International
- ~$7M increase in Boston recall return provision impacting Q3 results and full-year guidance

✓ Building towards long-range growth commitments

- Relaunched CereLink in select international markets and submitted 510k in the U.S.
- Advanced key growth drivers: IBBR PMA strategies for both SurgiMend and DuraSorb; next-generation Aurora Surgiscope
- Continued international expansion for DuraGen, CUSA, Mayfield, Duo LED lighting and electrosurgery

INTEGRA®
LIMIT UNCERTAINTY

Appendix

Non-GAAP Reconciliations

Third Quarter 2023 Financial Results

% of Revenues	Q3 2023	Q3 2022	Change	Q3 YTD 2023	Q3 YTD 2022	Change
Total Revenues	$382.4	$385.2	(0.7%)	$1,144.5	$1,159.6	(1.3%)
Gross Margin	57.1%	61.5%	-440BPS	57.5%	62.1%	-460BPS
Adj. Gross Margin[(1)]	64.6%	66.7%	-210BPS	66.5%	67.5%	-100BPS
Net Income	$19.5	$49.9	(60.9%)	$47.9	$127.6	(62.5%)
Adj. Net Income[(1)]	$60.5	$71.7	(15.6%)	$178.7	$202.0	(11.5%)
Adj. EBITDA Margin[(1)]	23.0%	27.3%	-430BPS	23.5%	26.0%	-250BPS
Diluted Shares Out (M)	79.8	83.4	(4.3%)	81.1	83.5	(2.8%)
Earnings per Share	$0.24	$0.60	(60.0%)	$0.59	$1.53	(61.4%)
Adj. Earnings per Share[(1)]	$0.76	$0.86	(11.6%)	$2.20	$2.42	(9.1%)

(1) These are non-GAAP financial measures. Please see the Appendix of this presentation for a reconciliation to the nearest GAAP measure.

Note: Numbers may not add due to rounding

Third Quarter 2023 Organic Growth Reconciliation

(In millions)	Q3 2023	Q3 2022	Q3 YTD 2023	Q3 YTD 2022
Neurosurgery	$209.2	$193.8	$607.9	$588.8
Instruments	$59.0	$55.9	$179.5	$166.1
Total Codman Specialty Surgical	**$268.2**	**$249.8**	**$787.4**	**$755.0**
Wound Reconstruction and Care	$88.1	$104.6	$280.1	$304.1
Private Label	$26.1	$30.8	$77.0	$100.5
Total Tissue Technologies	**$114.2**	**$135.4**	**$357.2**	**$404.7**
Total Reported Revenues	**$382.4**	**$385.2**	**$1,144.5**	**$1,159.6**
Revenues from divested products[(1)]	(0.0)	(4.6)	(0.2)	(17.9)
Revenues from discontinued products[(1)]	(1.4)	(1.9)	(4.6)	(6.3)
Revenues ex divested/ discontinued products	**$381.0**	**$378.7**	**$1,139.7**	**$1,135.4**
Impact of changes in currency exchange	(1.0)	-	7.7	-
Revenues from acquisitions[(2)]	(2.9)	-	(7.2)	-
Total Organic Revenues	**$377.1**	**$378.7**	**$1,140.3**	**$1,135.4**
Organic Revenue Growth	*-0.4%*		*0.4%*	
Boston Revenue impact	6.2	(21.0)	(1.8)	(63.5)
Total Organic Revenues ex Boston	**$383.3**	**$357.7**	**$1,138.5**	**$1,071.9**
Organic Revenue Growth ex Boston	*7.1%*		*6.2%*	

Note: Numbers may not add due to rounding

(1) Organic revenue has been adjusted for 2023 and 2022 to account for divestitures and discontinued products

(2) Revenue from acquisitions includes SIA

Third Quarter 2023 and 2022 (TTM) Adjusted Free Cash Flow Reconciliation

Note: Numbers may not add due to rounding

(In millions)	Q3 2023	Q3 2022	Q3 YTD 2023	Q3 YTD 2022	TTM 2023	TTM 2022
Net Cash from Operating Activities	$26.8	$68.3	$81.2	$179.1	$166.5	$248.4
Purchases of Property and Equipment	($13.1)	($9.2)	($42.4)	($27.9)	($56.9)	($55.3)
Free Cash Flow	**$13.7**	**$59.2**	**$38.8**	**$151.2**	**$109.7**	**$193.1**
Adjusted Net Income	$60.5	$71.7	$178.7	$202.0	$257.5	$274.2
Adjusted Free Cash Flow Conversion	**22.6%**	**82.5%**	**21.7%**	**74.9%**	**42.6%**	**70.4%**

Third Quarter 2023 Adjusted EBITDA Margin Reconciliation

Note: Numbers may not add due to rounding

(In millions)	Q3 2023	Q3 2022	Q3 YTD 2023	Q3 YTD 2022
GAAP Net Income	**$19.5**	**$49.9**	**$47.9**	**$127.6**
Depreciation	9.7	10.3	29.9	30.1
Intangible asset amortization	20.9	19.2	62.1	58.7
Other (income), net	(0.3)	(2.0)	(1.0)	(4.9)
Interest expense, net	8.5	9.5	25.0	30.1
Income tax expense/(benefit)	(0.9)	8.9	4.3	22.1
Acquisition, divestiture and integration-related charges[(1)]	5.8	(13.8)	18.1	(19.6)
Structural optimization charges	5.9	10.1	15.0	24.6
Boston Recall	5.6	-	33.7	-
EU Medical Device Regulation	13.5	13.2	34.2	33.0
Total of non-GAAP adjustments:	68.6	55.4	221.3	174.0
Adjusted EBITDA	**$88.1**	**$105.3**	**$269.2**	**$301.7**
Total Revenues	$382.4	$385.2	$1,144.5	$1,159.6
Adjusted EBITDA Margin	**23.0%**	**27.3%**	**23.5%**	**26.0%**

(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics, ACell and SIA acquisitions and the divestiture of Extremity Orthopedics, TWC and includes banking, legal, consulting, systems, and other income and expenses.

Third Quarter 2023 Adjusted EPS Reconciliation

Note: Numbers may not add due to rounding

(In millions)	Q3 2023	Q3 2022	Q3 YTD 2023	Q3 YTD 2022
GAAP Net Income	**$19.5**	**$49.9**	**$47.9**	**$127.6**
Acquisition, divestiture and integration-related charges[(1)]	5.8	(13.8)	18.1	(19.6)
Structural optimization charges	5.9	10.1	15.0	24.6
Boston Recall	5.6	-	33.7	-
EU Medical Device Regulation	13.5	13.2	34.2	33.0
Intangible asset amortization expense	20.9	19.2	62.1	58.7
Estimated income tax impact from adjustments and other items	(10.7)	(6.9)	(32.3)	(22.3)
Total of non-GAAP adjustments:	41.0	21.8	130.8	74.4
Adjusted Net Income	**$60.5**	**$71.7**	**$178.7**	**$202.0**
Adjusted Diluted Net Income per Share	**$0.76**	**$0.86**	**$2.20**	**$2.42**
Weighted average common shares outstanding for diluted net income from continuing operations per share	79.8	83.4	81.1	83.5

(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics, ACell and SIA acquisitions and the divestiture of Extremity Orthopedics, TWC and includes banking, legal, consulting, systems, and other income and expenses.

Third Quarter 2023 Gross Margin Reconciliation

Note: Numbers may not add due to rounding

(In millions)	Q3 2023	Q3 2022	Q3 YTD 2023	Q3 YTD 2022
Reported Gross Profit	**$218.3**	**$236.7**	**$658.2**	**$720.2**
Structural optimization charges	4.0	2.8	10.3	9.7
Acquisition, divestiture and integration-related charges[(1)]	0.4	0.2	3.0	0.9
Boston Recall	5.5	-	33.6	-
EU Medical Device Regulation	1.3	1.3	3.6	3.2
Intangible asset amortization expense	17.7	16.1	52.8	48.3
Adjusted Gross Profit	**$247.2**	**$257.0**	**$761.5**	**$782.4**
Total Revenues	$382.4	$385.2	$1,144.5	$1,159.6
Adjusted Gross Margin	**64.6%**	**66.7%**	**66.5%**	**67.5%**

(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery and SIA acquisition and the divestiture of Extremity Orthopedics.

Third Quarter 2023 Adjusted SG&A Reconciliation

Note: Numbers may not add due to rounding

(In millions)	Q3 2023	Q3 2022	Q3 YTD 2023	Q3 YTD 2022
Reported SG&A	**$161.9**	**$143.8**	**$493.5**	**$464.4**
Structural optimization charges	1.9	7.4	4.8	14.7
Acquisition, divestiture and integration-related charges[(1)]	6.6	(12.2)	17.1	(14.0)
Boston Recall	0.1	-	0.1	-
EU Medical Device Regulation	5.7	5.7	15.3	11.7
Adjusted SG&A	**$147.6**	**$142.9**	**$456.1**	**$452.0**
Total Revenues	$382.4	$385.2	$1,144.5	$1,159.6
Adjusted SG&A (% of Revenues)	**38.6%**	**37.1%**	**39.9%**	**39.0%**

(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics, ACell and SIA acquisitions and the divestiture of Extremity Orthopedics, TWC and includes banking, legal, consulting, systems, and other income and expenses.

Third Quarter 2023 Net Debt Reconciliation

Capitalization		
($ in millions)	**9/30/2023**	**12/31/2022**
Short-term borrowings under senior credit facility	9.7	38.1
Long-term borrowings under senior credit facility	850.1	733.1
Borrowings under securitization facility	75.7	104.7
Long-term convertible securities	569.5	567.3
Deferred financing costs netted in the above	10.7	11.4
Cash & Cash Equivalents	(273.7)	(456.7)
Net Debt	**$ 1,242.0**	**$ 998.0**